Literature DB >> 17158139

Sex: a major predictor of remission in early rheumatoid arthritis?

K Forslind1, I Hafström, M Ahlmén, B Svensson.   

Abstract

BACKGROUND: The treatment goal of early rheumatoid arthritis is remission. This study reports remission rates in clinical practice using a cohort of patients with early rheumatoid arthritis.
METHODS: 698 patients with early rheumatoid arthritis were included. Mean age at inclusion was 58 years and mean disease duration was 6.4 months; 64% of the patients were women, 56% were positive for antibodies to cyclic citrullinated peptide and 60% were positive for rheumatoid factor. Remission was defined as a disease activity score <2.6, with or without ongoing treatment with drugs for rheumatoid arthritis.
RESULTS: After 2 years, 261 of 689 patients were in remission (37.9%), and after 5 years, the remission rate was 38.5%. However, only 26.1% were in remission at both these time points. Multiple logistic regression analyses found sex to be a main predictor for remission. Thus, significantly fewer women were in remission after 2 years (32.1% v 48%, p = 0.001) after 5 years (30.8% v 52.4%, p = 0.001) and at both these time points (19.1% v 39.3%, p = 0.001). Although disease activity was not with certainty more pronounced in women at onset of disease, the disease course became markedly worse in women. The disparity in remission frequency between women and men could not be explained by differences in disease duration, age or treatment with disease modifying antirheumatic drugs or glucocorticoids.
CONCLUSIONS: Early remission of rheumatoid arthritis by 28-joint Disease Activity Score<2.6 was as frequent or more frequent in this study than in most previous reports. Importantly, women had more severe disease with a considerably lower remission rate than men, although the disease activity before treatment seemed similar.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158139      PMCID: PMC1798403          DOI: 10.1136/ard.2006.056937

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

Review 1.  What is the natural history of rheumatoid arthritis?

Authors:  W E Ollier; B Harrison; D Symmons
Journal:  Best Pract Res Clin Rheumatol       Date:  2001-03       Impact factor: 4.098

2.  Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis.

Authors:  Alejandro Balsa; Loreto Carmona; Isidoro González-Alvaro; Miguel Angel Belmonte; Xavier Tena; Raimon Sanmartí
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

3.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors:  Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

4.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.

Authors:  M E Weinblatt; E C Keystone; D E Furst; A F Kavanaugh; E K Chartash; O G Segurado
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

5.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention.

Authors:  Robert B M Landewé; Maarten Boers; Arco C Verhoeven; Rene Westhovens; Mart A F J van de Laar; Harry M Markusse; J Christiaan van Denderen; Marie Louise Westedt; Andre J Peeters; Ben A C Dijkmans; Piet Jacobs; Annelies Boonen; Désirée M F M van der Heijde; Sjef van der Linden
Journal:  Arthritis Rheum       Date:  2002-02

Review 6.  Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years.

Authors:  B Harrison; D Symmons
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

7.  Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis.

Authors:  S Kuiper; A M van Gestel; H L Swinkels; T M de Boo; J A da Silva; P L van Riel
Journal:  J Rheumatol       Date:  2001-08       Impact factor: 4.666

Review 8.  Prognostic factors in early rheumatoid arthritis.

Authors:  D L Scott
Journal:  Rheumatology (Oxford)       Date:  2000-06       Impact factor: 7.580

9.  Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options.

Authors:  B Svensson; M Ahlmén; K Forslind
Journal:  Clin Exp Rheumatol       Date:  2003 May-Jun       Impact factor: 4.473

10.  The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years.

Authors:  Birgitta Tengstrand; Monica Ahlmén; Ingiäld Hafström
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

View more
  70 in total

1.  Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study.

Authors:  Jeffrey Lee; Randal Mason; Liam Martin; Cheryl Barnabe
Journal:  Rheumatol Int       Date:  2014-03-30       Impact factor: 2.631

2.  The good EULAR response at the first year is strongly predictive of clinical remission in rheumatoid arthritis: results from the TARAC cohort.

Authors:  Budsakorn Darawankul; Sumapa Chaiamnuay; Rattapol Pakchotanon; Paijit Asavatanabodee; Pongthorn Narongroeknawin
Journal:  Clin Rheumatol       Date:  2014-07-26       Impact factor: 2.980

3.  HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis.

Authors:  Kyung-Eun Lee; Sung-Eun Choi; Haimuzi Xu; Ji-Hyoun Kang; Dong-Jin Park; Shin-Seok Lee
Journal:  Rheumatol Int       Date:  2017-09-27       Impact factor: 2.631

4.  Women's accounts of help-seeking in early rheumatoid arthritis from symptom onset to diagnosis.

Authors:  Anne Townsend; Catherine L Backman; Paul Adam; Linda C Li
Journal:  Chronic Illn       Date:  2014-02-24

Review 5.  Cellular and molecular perspectives in rheumatoid arthritis.

Authors:  Douglas J Veale; Carl Orr; Ursula Fearon
Journal:  Semin Immunopathol       Date:  2017-05-15       Impact factor: 9.623

Review 6.  Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications.

Authors:  Francisco Espinoza; Sylvie Fabre; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-13       Impact factor: 5.346

Review 7.  Sex and Management of Rheumatoid Arthritis.

Authors:  Ennio Giulio Favalli; Martina Biggioggero; Chiara Crotti; Andrea Becciolini; Maria Gabriella Raimondo; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

8.  Locating sex-specific evidence on clinical questions in MEDLINE: a search filter for use on OvidSP.

Authors:  Clara J Moerman; Rikie Deurenberg; Joke A Haafkens
Journal:  BMC Med Res Methodol       Date:  2009-04-14       Impact factor: 4.615

Review 9.  Androgens in rheumatoid arthritis: when are they effectors?

Authors:  Maurizio Cutolo
Journal:  Arthritis Res Ther       Date:  2009-09-22       Impact factor: 5.156

10.  Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study.

Authors:  Tuulikki Sokka; Sergio Toloza; Maurizio Cutolo; Hannu Kautiainen; Heidi Makinen; Feride Gogus; Vlado Skakic; Humeira Badsha; Tõnu Peets; Asta Baranauskaite; Pál Géher; Ilona Ujfalussy; Fotini N Skopouli; Maria Mavrommati; Rieke Alten; Christof Pohl; Jean Sibilia; Andrea Stancati; Fausto Salaffi; Wojciech Romanowski; Danuta Zarowny-Wierzbinska; Dan Henrohn; Barry Bresnihan; Patricia Minnock; Lene Surland Knudsen; Johannes Wg Jacobs; Jaime Calvo-Alen; Juris Lazovskis; Geraldo da Rocha Castelar Pinheiro; Dmitry Karateev; Daina Andersone; Sylejman Rexhepi; Yusuf Yazici; Theodore Pincus
Journal:  Arthritis Res Ther       Date:  2009-01-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.